<code id='0D2543F26C'></code><style id='0D2543F26C'></style>
    • <acronym id='0D2543F26C'></acronym>
      <center id='0D2543F26C'><center id='0D2543F26C'><tfoot id='0D2543F26C'></tfoot></center><abbr id='0D2543F26C'><dir id='0D2543F26C'><tfoot id='0D2543F26C'></tfoot><noframes id='0D2543F26C'>

    • <optgroup id='0D2543F26C'><strike id='0D2543F26C'><sup id='0D2543F26C'></sup></strike><code id='0D2543F26C'></code></optgroup>
        1. <b id='0D2543F26C'><label id='0D2543F26C'><select id='0D2543F26C'><dt id='0D2543F26C'><span id='0D2543F26C'></span></dt></select></label></b><u id='0D2543F26C'></u>
          <i id='0D2543F26C'><strike id='0D2543F26C'><tt id='0D2543F26C'><pre id='0D2543F26C'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:leisure time    Page View:6134
          Two business miniatures talk to each other on coin stacks that are sandwiched by a syringe and a stethoscope — coverage from STAT
          Adobe

          For all the flak they get, the country’s four biggest pharmacy benefit managers reported a surprisingly tame average profit margin in the first three quarters of 2023: 4.5%, less than a third of their drugmaker peers.

          But don’t take their numbers as gospel, experts warned.

          advertisement

          “It’s really easy to move money around inside the books of a vertically integrated organization,” said Karen Van Nuys, a senior fellow at the USC Schaeffer Center for Health Policy and Economics. “If one segment of your vertically integrated organization is not publishing any financial data, it’s a good place to hide stuff.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?
          ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

          SusanGalbraith,AstraZeneca’sheadofcancerresearchanddevelopment,speaksataSTATeventin2023.MarieMillerf

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

          AdobeWhenitcomestobringinganexperimentaldrugtomarketandsellingit,NovoNordisk,themakeroftheweightloss